儿童变应性鼻炎合并支气管哮喘协同治疗及管理研究进展  

Research on collaborative treatment and management of allergic rhinitis and asthma in children

作　　者：刘晓颖(综述)[1] 向莉(审校)[1] 

机构地区：[1]首都医科大学附属北京儿童医院过敏反应科,北京100045

出　　处：《国际儿科学杂志》2016年第3期161-169,共9页International Journal of Pediatrics

基　　金：国家自然科学基金资助项目（81100022）;北京市科技专项资助项目（z131100006813044）

摘　　要：儿童变应性鼻炎和支气管哮喘常在同一个体共存，两者交互影响疾病进程及疾病严重程度。国内外研究显示给予变应性鼻炎合并哮喘患儿糖皮质激素、口服白三烯受体拮抗剂和皮下／舌下过敏原特异性免疫治疗，可协同治疗两种疾病。由于变应性鼻炎和哮喘均为慢性呼吸道疾病，需要长期随访并阶梯性调整用药，因而患儿及照护者的自主评估有助于疾病的协同管理，慢性疾病管理工具对疾病的协同管理亦是不可或缺的。重视儿童变应性鼻炎和哮喘协同治疗和管理，对提高治疗依从性，改善生活质量，减轻疾病负担有重要意义。Allergic rhinitis （AR）and bronchial asthma often coexist in the same individual, in which they influence development and severity of each other. Both domestic and foreign research has showed that Syn- ergistic treatment to children with AR and asthma could be achieved by inhaled corticosteroids （ ICS ）, oral leu- kotriene receptor antagonist and subcutaneous/sublingual allergen specific immunotherapy;coUaborative manage- ment will be realized by doctors＇ Comprehensive clinical assessment, children and caregivers＇ self-assessment and chronic disease management tools. Collaborative treatment and management is significant to children with both allergic rhinitis and asthma. In addition,it has an edge in improving compliance of children and their parents during the treatment, the quality of childrens＇ life, and reducing burden of the diseases.

关 键 词：儿童 变应性鼻炎 哮喘 治疗 疾病管理 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]